Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and Pembrolizumab With or Without FLOT in Neoadjuvant/Adjuvant Treatment for Gastric Cancer
NCT04745988Phase 2Active, not recruiting
- Sponsor
- National Cancer Center Hospital East
- Start
- Nov 2021
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, pembrolizumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by National Cancer Center Hospital East. Started Nov 2021; status: active, not recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04745988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745988.